MarketCapExport financials
TherapeuticsMD (TXMD)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
TherapeuticsMD Income Statement 2025-2009 | TXMD
Brief overview of financial results at TherapeuticsMD
The comparison covers a five-year financial horizon. Revenue at TherapeuticsMD moved from $64.9 million in 2020 to $3 million in 2025. The cumulative result was −95.3%, corresponding to roughly −45.8% per year. The negative rate indicates weakening core operations.
The operating result measured by EBITDA moved from −154 million dollars to −4 million dollars, or +97.4%. EBITDA grew faster than revenue, indicating positive operating leverage. EBITDA margin moved from −238.2% to −132.6%. The business generated more EBITDA from each unit of revenue.
The final result was −184 million dollars initially and −569 thousand dollars in the final year. The loss narrowed, although sustainable profitability has not yet returned.
Conclusion
The figures do not all move in the same direction. Key strengths include higher operating efficiency and a stronger final result. The main areas of concern are limited revenue growth and limited operating profitability. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement TherapeuticsMD
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
23 M | 22.9 M | 23.9 K | 32.1 M | 119 M | 450 M | 584 M | 1.15 B | 1.27 B | 1.11 B | 1.24 B | 608 M | 860 M | 294 M | 128 M | 283 B | - |
Shares |
11.6 M | 11.5 M | 10.4 K | 9.03 M | 7.96 M | 273 M | 246 M | 225 M | 206 M | 196 M | 173 M | 150 M | 128 M | 91.6 M | 62.5 M | 55.5 M | - |
Historical Prices |
1.99 | 1.99 | 2.29 | 3.56 | 15 | 82.5 | 112 | 262 | 294 | 290 | 358 | 203 | 329 | 160 | 100 | 5.1 K | 1.68 K |
Net Income |
-569 K | -2.18 M | -10.3 M | 112 M | -172 M | -184 M | -176 M | -133 M | -76.9 M | -89.9 M | -85.1 M | -54.2 M | -28.4 M | -35.1 M | -12.9 M | -2.87 M | - |
Revenue |
3.02 M | 1.76 M | 1.3 M | 70 M | 2.57 M | 64.9 M | 49.6 M | 16.1 M | 16.8 M | 19.4 M | 20.1 M | 15 M | 8.78 M | 3.82 M | 2.09 M | - | - |
Cost of Revenue |
- | - | - | 1.4 M | 1.4 M | 16 M | 6.34 M | 2.74 M | 2.64 M | 4.19 M | - | - | - | - | - | - | - |
Gross Profit |
- | - | 1.3 M | 68.6 M | 1.17 M | 48.9 M | 43.3 M | 13.4 M | 14.1 M | 15.2 M | 15.6 M | 11.4 M | 6.82 M | 2.47 M | 1.14 M | - | - |
Operating Income |
-4.39 M | -6.11 M | -8.52 M | 1.19 M | -79.6 M | -156 M | -151 M | -130 M | -77.6 M | -90.3 M | -85.2 M | -54 M | -25.8 M | -16.1 M | -5.43 M | - | - |
Interest Expense |
- | - | 300 K | 200 K | 32.9 M | 28.6 M | 17.4 M | 4.68 M | - | - | - | 1.17 M | 1.91 M | 1.91 M | 64.4 K | - | - |
EBITDA |
-4.01 M | -5.6 M | -7.6 M | 2.38 M | -78.8 M | -154 M | -151 M | -130 M | -77.4 M | -90.1 M | -85.1 M | -54 M | -25.8 M | -16.1 M | -5.37 M | - | - |
Operating Expenses |
7.41 M | 7.87 M | 9.82 M | 67.4 M | 80.7 M | 204 M | 195 M | 144 M | 91.8 M | 105 M | 101 M | 65.4 M | 32.6 M | 18.6 M | 6.57 M | - | - |
General and Administrative Expenses |
6.85 M | 6.1 M | 8.9 M | 56.7 M | 80.7 M | 193 M | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement TherapeuticsMD
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
11.6 M | 11.6 K | - | 11.6 M | 11.6 M | 11.6 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 10.7 M | 10.2 M | 9.75 M | 9.5 M | 9.26 M | 8.75 M | 8.61 M | 8.6 M | 8.44 M | 7.88 M | 6.94 M | 300 M | 273 M | 272 M | 271 M | 271 M | 241 M | 241 M | 241 M | 240 M | 228 M | 217 M | 217 M | 216 M | 208 M | 203 M | 198 M | 197 M | 197 M | 196 M | 195 M | 178 M | 177 M | 173 M | 163 M | 156 M | 152 M | 145 M | 145 M | 145 M | 131 M | 131 M | 103 M | 99.8 M | 95.9 M | 86.1 M | 84.6 M | 83 M | 58.4 M | 57.5 M | 55.7 M |
Net Income |
-653 K | 95 K | - | 152 K | 551 K | -653 K | - | -609 K | -1.09 M | -734 K | - | -3.38 M | -2.41 M | -3.6 M | - | -29 M | 112 M | -49 M | -43 M | -47.4 M | -42.7 M | -39.4 M | -42.1 M | -32.6 M | -52 M | -56.8 M | -49.4 M | -32 M | -55.2 M | -39.5 M | -39.4 M | -35.6 M | -33.2 M | -24.4 M | -21.4 M | -14.7 M | -19.7 M | -21.2 M | -22.8 M | -25 M | -21.1 M | -20.9 M | -17.5 M | -19.5 M | -27.2 M | -20.9 M | -16.3 M | -17.8 M | -10.9 M | -9.18 M | -8.36 K | -7.67 K | -6.01 K | -6.38 K | -5.73 K | -4.25 K | -11.8 K | -13.3 K | - | -1.49 M | -1.07 M | -774 K |
Revenue |
952 K | 724 K | - | 784 K | 952 K | 393 K | - | 547 K | 234 K | 313 K | - | -53 K | 437 K | 416 K | - | 354 K | 348 K | 695 K | 18.7 M | 25.4 M | 23 M | 19.9 M | 22.6 M | 19.3 M | 10.7 M | 12.3 M | 15.9 M | 23.7 M | 6.08 M | 3.95 M | 5.09 M | 3.47 M | 3.76 M | 3.77 M | 4.12 M | 4.42 M | 4.25 M | 3.99 M | 4.49 M | 5.54 M | 4.4 M | 4.93 M | 5.63 M | 5.19 M | 4.85 M | 4.48 M | 4.26 M | 4.19 M | 3.75 M | 2.83 M | 2.86 K | 2.29 M | 2.08 M | 1.54 M | 1.24 K | 1.04 M | 819 K | 722 K | - | 540 K | 508 K | 486 K |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 354 K | 348 K | 695 K | - | 5.28 M | 4.13 M | 4.69 M | - | 3.28 M | 4.4 M | 2.72 M | - | 1.44 M | 1.25 M | 763 K | - | 699 K | 454 K | 634 K | - | 701 K | 682 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | -53 K | 437 K | 416 K | - | 17.1 M | 23.8 M | 14.5 M | 13.9 M | 20.1 M | 18.9 M | 15.2 M | 17 M | 16.1 M | 6.3 M | 9.54 M | 13 M | 22.3 M | 4.83 M | 3.18 M | 4.14 M | 2.78 M | 3.31 M | 3.14 M | 3.53 M | 3.72 M | 3.57 M | 3.33 M | 3.78 M | 4.3 M | 3.27 M | 3.82 M | 4.4 M | 4 M | 3.82 M | 3.43 M | 3.38 M | 3.12 M | 2.86 M | 2 M | 2.4 K | 1.65 K | 1.62 K | 1.16 K | 908 | 729 | 447 | 386 | - | 298 K | 269 K | 282 K |
Operating Income |
-695 K | -723 K | - | -862 K | -695 K | -871 K | - | -1.13 M | -2.79 M | -1.14 M | - | -1.77 M | -2.47 M | -2.67 M | - | -14.5 M | -14.9 M | -17.9 M | -35.4 M | -39.9 M | -35.2 M | -29.3 M | -34.6 M | -25 M | -45 M | -50.9 M | - | -27.1 M | -41.6 M | -38.1 M | - | -34.4 M | -33 M | -24.7 M | - | -14.8 M | -19.8 M | -21.3 M | - | -25.1 M | -21.2 M | -21 M | - | -19.5 M | -27.3 M | -20.9 M | - | -17.8 M | -10.9 M | -8.95 M | - | -7.24 M | -5.62 M | -4.94 M | - | -3.91 M | -3.97 M | -2.87 M | - | -1.44 M | -1.05 M | -771 K |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | 20 K | 45 K | 50 K | - | 4.83 M | 11.7 M | 14.4 M | - | 7.52 M | 7.6 M | 10.2 M | - | 7.68 M | 7.03 M | 6.26 M | - | 5.6 M | 4.03 M | 2.09 M | - | 2.05 M | 531 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 150 | 1.17 M | - | 134 K | 1.15 M | 102 K | - | 16.5 K | 232 | - |
EBITDA |
-682 K | -629 K | - | -766 K | -599 K | -776 K | - | -1.04 M | -2.61 M | -1.01 M | - | - | -2.34 M | -2.64 M | - | -14.3 M | -14.7 M | -17.5 M | -35.4 M | -36.8 M | -33.1 M | -28.3 M | -34.6 M | -24.7 M | -44.8 M | -49.9 M | - | -26.9 M | -41.5 M | -38 M | - | -34.3 M | -33 M | -24.7 M | - | -14.8 M | -19.8 M | -21.2 M | - | -25.1 M | -21.2 M | -21 M | - | -19.5 M | -27.2 M | -20.9 M | - | -17.8 M | -10.9 M | -8.94 M | - | -7.2 M | -5.61 M | -4.93 M | 28.8 K | -3.9 M | -3.96 M | -2.85 M | - | -1.4 M | -1.02 M | -758 K |
Operating Expenses |
1.65 M | 1.45 M | - | 1.65 M | 1.65 M | 1.26 M | - | 1.68 M | 3.02 M | 1.46 M | - | 1.72 M | 2.91 M | 3.08 M | - | 14.5 M | 14.9 M | 17.9 M | - | 60 M | 54 M | 44.5 M | - | 41 M | 51.3 M | 60.5 M | - | 49.3 M | 46.5 M | 41.3 M | - | 37.1 M | 36.3 M | 27.9 M | - | 18.5 M | 23.4 M | 24.6 M | - | 29.4 M | 24.5 M | 24.8 M | - | 23.5 M | 31.1 M | 24.4 M | - | 21 M | 13.8 M | 11 M | - | 8.88 M | 7.23 M | 6.1 M | - | 4.64 M | 4.42 M | 3.25 M | - | 1.74 M | 1.32 M | 1.05 M |
General and Administrative Expenses |
1.55 M | 1.35 M | - | 1.52 M | 1.55 M | 1.08 M | - | 1.58 M | 1.58 M | 1.32 M | - | 1.59 M | 2.78 M | 3.06 M | - | 14.2 M | 14.6 M | 17.5 M | - | 28.4 M | 19.9 M | 18.4 M | - | 16.6 M | 18.7 M | 57.2 M | - | 45.1 M | 41.4 M | 34.9 M | - | 30.4 M | 29.5 M | 20.8 M | - | 12.1 M | 14.6 M | 16.8 M | - | 14.7 M | 10.6 M | 9.68 M | - | 7.06 M | 6.87 M | 6.16 M | - | 6.04 M | 5.54 M | 5.03 M | - | 4.75 M | 5.48 M | 4.53 M | - | 2.92 M | 3.57 M | 2.83 M | - | 64.6 K | 58.6 K | 985 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company TherapeuticsMD (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
France
Canada
China
Irlanda
Schweden
